- New and efficient process for the preperation of cabergoline and its intermediates
-
This invention relates to a new and efficient process for the production of dopamine agonists such as Cabergoline and the intermediates thereof.
- -
-
Page/Page column 12
(2008/12/08)
-
- New crystal form of cabergoline
-
The present invention relates to a new needle-form crystalline cabergoline form L, its preparation from halogenated aromatic solvents and aliphatic hydrocarbons and its use in pharmaceutical composition.
- -
-
Page/Page column 7
(2008/12/07)
-
- PROCESS FOR THE PREPARATION OF CRYSTAL FORMS OF CABERGOLINE VIA NOVEL STABLE SOLVATES OF CABERGOLINE
-
The present invention relates to a process for producing cabergoline crystal forms. The process comprises preparation of the desired solvate of cabergoline from a solution of cabergoline in chloroaromatic solvents. Afterwards cabergoline crystal form is prepared by recovery from a solvate of cabergoline by drying or with desolvating in a solvent media.
- -
-
Page/Page column 10
(2008/12/05)
-
- PROCESS FOR THE PREPARATION OF AMORPHOUS CABERGOLINE
-
The present invention relates to processes for the preparation of amorphous cabergoline by agitated thin film drying or spray drying.
- -
-
Page/Page column 4,5
(2008/12/07)
-
- Production of Cabergoline and Novel Polymorphic Form Thereof
-
The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.
- -
-
Page/Page column 4; 1
(2008/06/13)
-
- IMPROVED PROCESS FOR MAKING CABERGOLINE
-
The invention relates to a process for preparing cabergoline of formula (1).
- -
-
Page/Page column 13
(2010/11/23)
-
- NOVEL PROCESS FOR PRODUCTION OF CABERGOLINE
-
A process for preparing cabergoline (I) from ergoline-8β-carboxylic acid ester (XIII) comprising the following steps. (a) reacting an ergoline-8β-carboxylic acid ester of formula (XIII), wherein R1 represents a C1-4 alkyl group, in the presence of a catalyst (i) with a compound of formula (XIV), X-COOR2 (XIV) wherein R2 is an optionally substituted straight or branched C1-6 alkyl group, X represents a bromine or chlorine atom, or (ii) with a compound of formula (XV), O(COOR2)2 (XV) wherein R2 is a group as defined above; (b) reacting the obtained carbamate derivative of formula (XVI) with 3-(dimethylamino)-propylamine (DMAPA) in the presence of a catalyst; (c) reacting the obtained ergoline-8β-carboxamide derivative of formula (XVII) with ethyl isocyanate (EtNCO) in the presence of ligand(s) and Ib and IIb metal group salt catalysts; (d) reacting the obtained protected N-acylurea derivative of formula (XVIII) with a strong aqueous inorganic acid (aq./acid); (e) reacting the obtained secondary amine (XIX) with an electrophyl allyl alcohol derivative in the presence of a palladium or nickel containing catalyst and optionally in the presence of ligand(s) to form cabergoline (I). The intermediates of (XVI), (XVII), (XVIII) and (XIX) are novel. The polymorphic amorphous form of Cabergoline (I) and the production thereof.
- -
-
Page/Page column 22
(2008/06/13)
-
- Preparation of cabergoline
-
The present invention discloses a method for preparing cabergoline form I by combining cabergoline and a solvent comprising ethylbenzene to form a solvate and obtaining form I from the solvate. Also disclosed in a method for preparing cabergoline form I by combining cabergoline and a first solvent to form a solution and additionally including a second solvent to the solution, followed by crystallization to form cabergoline form I. Further disclosed is a solvate form of cabergoline comprising cabergoline and ethylbenzene and, optionally, n-heptane.
- -
-
Page/Page column 2
(2010/02/14)
-
- Forms of cabergoline
-
The invention provides methods for preparing amorphous physical form of cabergoline, and solvate form A of cabergoline useful in the preparation of the first mentioned physical form. A method for treating a prolactin disorder with medicaments prepared from amorphous physical form of cabergoline and solvate form A of cabergoline is also disclosed.
- -
-
-
- POLYMORPHS OF CABERGOLINE
-
Provided are new crystalline Forms, VIII, IX, XI, XII, XIV, XV, XVI, XVII, and XVIII of cabergoline. Also provided are novel processes for preparation of cabergoline Form I, Form II, Form VII, and amorphous cabergoline.
- -
-
-
- A practical synthesis of cabergoline
-
Cabergoline is an N-acylurea derived from 9,10-dihydrolysergic acid, which is a potent prolactin inhibitor. It is marketed by Pharmacia as Dostinex for the treatment of hyperprolactinemia and is currently under active development for the treatment of a variety of CNS disorders. In the existing process, the N-acylurea is formed by the reaction of an amide with a large excess of ethyl isocyanate at elevated temperatures. An improved process was developed that eliminates this hazardous reaction. The amide is reacted with phenyl chloroformate and then with ethylamine, which provides a mild and efficient means of forming the unsymmetrical N-acylurea.
- Ashford, Scott W.,Henegar, Kevin E.,Anderson, Andrew M.,Wuts, Peter G. M.
-
p. 7147 - 7150
(2007/10/03)
-
